SCHEMBL4242291

SCHEMBL4242291

COC(=O)NCc1ccccc1-c1ccccc1C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 12/20 0.64
MAPK1 P28482 1/20 0.55
RAB9A P51151 1/20 0.49
HTT P42858 2/20 0.49
HPGD P15428 1/20 0.46
FOLH1 Q04609 1/20 0.46
KCNA3 P22001 2/20 0.45
KCNK3 O14649 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL498661 0.86 KCNA5 (0.67) KCNA5MAPK1RAB9AHTTKCNA3
SCHEMBL4237017 0.85 KCNA5 (0.67) KCNA5MAPK1RAB9AHTTFOLH1
SCHEMBL2207411 0.83 KCNA5 (0.68) KCNA5HTTKCNA3KCNK3
SCHEMBL4239368 0.83 PTPN11 (0.51) KCNA5MAPK1RAB9AKCNA3KCNK3
SCHEMBL4244489 0.82 KCNA5 (0.57) KCNA5MAPK1RAB9AHPGD
SCHEMBL4241477 0.80 KCNA5 (0.66) KCNA5MAPK1RAB9AHTTHPGD
SCHEMBL9664850 0.80 KCNA5 (0.52) KCNA5RAB9AHTTHPGD
SCHEMBL4236628 0.80 KCNA5 (0.53) KCNA5MAPK1RAB9AHTTHPGD
SCHEMBL2205331 0.79 KCNA5 (1.00) KCNA5MAPK1KCNA3KCNK3
SCHEMBL2634370 0.79 KCNK3 (0.66) KCNA5MAPK1RAB9AHTTKCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2004-05-27 US disclosed
US-6686395-B2 THERAPY OF A CARDIAC ARRYTHMIA WHICH CAN BE ELIMINATED BY ACTION POTENTIAL PROLONGATION; POTASSIUM CHANNEL MODULATOR AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-02-03 US disclosed
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed
US-6531495-B1 Potassium channel AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, KCNH1 KCNA5 104/4885MAPK1 2051/4885RAB9A 1604/4885
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them MLLT3, RYR2, CACNA1E KCNA5 90/4885MAPK1 2294/4885RAB9A 1634/4885
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, CACNA1E KCNA5 97/4885MAPK1 2117/4885RAB9A 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.